TrialJournal for immunotherapy of cancer2017

Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab.

Philip Friedlander et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.